Kathrin Schwarte

Oct 4, 2023 | psychiatrist.com | Emma Sampson |Natalie T. Mills |Hikaru Hori |Kathrin Schwarte

ABSTRACTObjective: Major depressive disorder (MDD) remains difficult to treat, with many patients resistant to existing treatments or experiencing relapse. Cognitive dysfunction is associated with more severe clinical outcomes. Vortioxetine has shown efficacy in remediating depression-associated cognitive impairment. Anti-inflammatory augmentation of antidepressants is a new strategy in treating depression and has not previously been assessed for effects on cognition in depression.